Portola enters deals for andexanet alfa in Japan worth up to $120 million

1 February 2016

US pharma majors Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) have entered into a collaboration agreement with Portola Pharmaceuticals (Nasdaq: PTLA) to develop and commercialize the investigational agent andexanet alfa in Japan.

Andexanet alfa, which is in Phase III clinical development in the USA and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban). The news pushed Portola’s shares up 3.33% to $34.13 in mid-morning trading.

Separately, Portola has entered into a clinical collaboration agreement with German drug major Bayer (BAYN: DE) to include its Factor Xa inhibitor Xarelto (rivaroxaban) in this clinical development program in Japan.
Three oral Factor Xa inhibitors are currently on the market in Japan - Bristol-Myers and Pfizer's apixaban, Bayer HealthCare's rivaroxaban, and Daiichi Sankyo's (TYO: 4568)Lixiana (edoxaban) - but an antidote is not yet approved. A universal antidote for Factor Xa inhibitors is needed for certain patients in Japan, as the clinical use of these novel oral anticoagulants is growing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK